GLP-1 drug and diet study for Crohn's disease patients
Treatments studied
Part of Digestive system clinical trials.
This study tests a drug that helps with weight loss and blood sugar (called a GLP-1 receptor agonist) combined with a special diet to see if it can improve symptoms in people with mild Crohn's disease. You may join if you have Crohn's, a BMI of 27 or higher, and are already on a stable dose of a TNF blocker.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with Crohn's disease
- Your Crohn's symptoms are mild (based on a score between 5 and 7 on a standard scale)
- Your BMI is 27 or higher (you are considered overweight or obese)
- You have been taking a stable dose of a TNF blocker (a type of biologic medicine) for your Crohn's
- You do not have diabetes, a history of certain thyroid cancers, or severe digestive issues like constant nausea, vomiting, or blockages
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adding a special diet (called CDED) to a biologic medicine (infliximab or adalimumab) helps control Crohn's disease better than the medicine alone. It may reduce inflammation and improve symptoms.
This study tests whether a special diet using a nutritional supplement can reduce inflammation and improve symptoms in people with active Crohn's disease affecting the small intestine. It aims to see how the diet changes gut bacteria and body composition.
This study looks at how a specific amino-acid (threonine) diet affects adults with Crohn’s disease and signs of intestinal inflammation. It may help researchers understand what dietary protein needs could support more stable disease.
This study tests a new drug called JNJ-78934804 for people with moderate to severe Crohn's disease who have not responded well to or can't tolerate current treatments. The goal is to see if this drug can reduce inflammation and symptoms in the digestive tract.
This study tests whether a specially designed anti-inflammatory American diet can help control mild to moderate Crohn's Disease symptoms. Participants will follow a diet plan, with guidance from the research team, to see if it reduces inflammation and improves quality of life.
This study tests a medicine called tirzepatide to see if it can help people with active Crohn’s disease who have not responded to multiple prior treatments. It focuses on how the drug might work beyond just reducing inflammation.
Hear when a new Crohn Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.